A study among pulmonary tuberculosis patients under the treatment of directly observed treatment short course with special reference to liver function in tertiary care hospital


  • C. Paranthakan Department of Internal Medicine, Thanjavur Medical College, Thanjavur, Tamilnadu, India
  • P. K. Govindarajan Department of Community Medicine, Raja Muthiah Medical College, Annamalai University, Annamalainagar, Tamilnadu, India




DOTS, Liver function, Serum albumin


Background: Directly observed treatment short course is the most effective life saving measure among the patients suffering from tuberculosis. Drug induced hepatotoxicity is one of the major side of anti-tuberculosis drugs which causes to withdraw the drugs. The objective of the study was to find out certain variables like age, sex and BMI among the patients with pulmonary tuberculosis and to find out liver function after intake of anituberculosis drugs.

Methods: The patients diagnosed first time with pulmonary tuberculosis by sputum positive attending RNTCP DOTS Cell at tertiary care hospital were selected for this study.95 patients enrolled in this study during six months period and they were followed another six months to find out the status of liver function. BMI was measured, the investigation like serum albumin, liver function (aspartate aminotransferase (AST), alanine aminotransferase (ALT) alkaline phosphatase level test (ALP), serum bilirubin) were assessed at the time of initiation of anti-tuberculosis drugs and 2 weeks, 4 weeks and 24 weeks after the drugs. Chi-square test applied as a statistical tool.

Results: Among study population of 95, 54% were male and 46% were female. Nearly 62% of the patients were in the age group of 18 to 48. Around 57% of the patients were underweight according to BMI. The liver function test was abnormal after drugs in 5.2% of the study population.

Conclusions: This study shows that the tuberculosis affects the productive life of the population. The drugs given under DOTS did not harm majority of the patients that shows it is safe to administer the regime.


Kim DH, Kim HJ, Park SK, Kong SJ, Kim YS, Kim TH et al. Treatment outcomes and survival based on drug resistance patterns in multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010;182: 113-9.

Aktogu S, Yorgancioglu A, Cirak AK, Köse T, Dereli SM et al. Clinical spectrum of pulmonary and pleural tuberculosis: a report of 5,480 cases. Eur Respir J. 1996;9:2031-5.

Mittal C. Noncompliance to DOTS: how it can be decreased. Indian J Comm Med. 2011;36(1):27-30.

Yimer G, Aderaye G, Amogne W, Makonnen E, Aklillu E, Lindquist L et al. Anti-tuberculosis therapy-induced hepatotoxicity among ethiopian hiv-positive and negative patients. Plos One. March 2008;3(3):e1809.

Sharma SK, Balamurugan A, Saha PK, Mehra NK Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. American J Respir Crit Care Med. 2002;66(7):916-9.

Teleman M, Chee CB, Earnest A, Wang YT. Hepatotoxicity of tuberculosis chemotherapy under general programme conditions in Singapore. Intern J Tuberculosis Lung Dis. 2002;6(8):699-705.

Schaberg T, Rebhan K, Lode H. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J. 1996;9:2026-30.






Original Research Articles